Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
2 reports, 1 independent
Updated Fri 00:00
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Gilead Sciences
American company
Related events
- Bristol-Myers Squibb and Novo Nordisk are noted as competitors in the healthcare sector.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- Major pharmaceutical companies are competing for investment capital.
- BioNTech announced new partnerships with Genmab, Pfizer, Bristol-Myers Squibb, and Genentech.
- Pfizer and Nexentis Technologies, both healthcare companies, are competing for investment, with Pfizer reporting higher revenue and earnings.